Top

Rheumatology International

Published in:

01-08-2016 | Cases with a Message

Successful treatment of refractory giant cell arteritis with etanercept

Authors: Masaaki Fujita, Yuya Tabuchi, Masato Yagita

Published in: Rheumatology International | Issue 8/2016

Excerpt

To the editor, …

Silva-Fernández L, Loza E, Martínez-Taboada VM, Blanco R, Rúa-Fiqueroa I, Pego-Reigosa JM et al (2014) Biological therapy for systemic vasculitis: a systemic review. Semin Arthritis Rheum 43:542–557CrossRefPubMed

Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33:1122–1128CrossRefPubMed

Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH et al (2007) Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis. Ann Intern Med 146:621–630CrossRefPubMed

Seror R, Baron G, Hachulla E, Debandt M, Larroche C, Puechal X et al (2014) Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomized controlled trial. Ann Rheum Dis 73:2074–2081CrossRefPubMed

Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, Lõpez-Longo J, Figueroa M, Belzunegui J et al (2008) A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 67:625–630CrossRefPubMed

Torrente SV, Gϋerri RC, PérezGarcia C, Benito P, Carbonell J (2007) Amaurosis in patients with giant cell arteritis: treatment with anti-tumour necrosis factor-α. Intern Med J 37:280–281CrossRefPubMed

Airò P, Antonioli CM, Vianelli M, Toniati P (2002) Anti-tumor necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology 41:347–349CrossRefPubMed

Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM (2007) Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol 26:1353–1355CrossRefPubMed

Cantini F, Niccoli L, Salvarani C, Padula A, Olivier I (2001) Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44:2933–2935CrossRefPubMed

10.

Hernández-Rodríguez J, Segarra M, Vilardell C, Sánchez M, García-Martínez A, Esteban MJ et al (2004) Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology 43:294–301CrossRefPubMed

11.

García-Martínez A, Hernández-Rodríguez J, Espígol-Frigolé G, Prieto-González S, Butjosa M, Segarra M et al (2010) Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res 62:835–841CrossRef

Title: Successful treatment of refractory giant cell arteritis with etanercept
Authors: Masaaki Fujita
Yuya Tabuchi
Masato Yagita
Publication date: 01-08-2016
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 8/2016
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-016-3521-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Successful treatment of refractory giant cell arteritis with etanercept

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2016

Is neutrophil-to-lymphocyte ratio valid to predict organ involvement in Henoch–Schönlein purpura?

Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials

Abducens nerve palsy in a girl with incomplete Kawasaki disease

A 5-year-old boy with only fever and giant coronary aneurysms: the enigma of Kawasaki disease?

Prevalence and predictors of unsupervised walking and physical activity in a community population of women with fibromyalgia

Efficacy of tocilizumab for psychiatric symptoms associated with relapsing polychondritis: the first case report and review of the literature

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page